rhc 3164 has been researched along with 6-cyano-7-nitroquinoxaline-2,3-dione in 1 studies
| Studies (rhc 3164) | Trials (rhc 3164) | Recent Studies (post-2010) (rhc 3164) | Studies (6-cyano-7-nitroquinoxaline-2,3-dione) | Trials (6-cyano-7-nitroquinoxaline-2,3-dione) | Recent Studies (post-2010) (6-cyano-7-nitroquinoxaline-2,3-dione) |
|---|---|---|---|---|---|
| 6 | 0 | 1 | 2,698 | 1 | 353 |
| Protein | Taxonomy | rhc 3164 (IC50) | 6-cyano-7-nitroquinoxaline-2,3-dione (IC50) |
|---|---|---|---|
| Glutamate receptor 1 | Homo sapiens (human) | 1.02 | |
| Glutamate receptor 2 | Homo sapiens (human) | 1.02 | |
| Glutamate receptor 3 | Homo sapiens (human) | 1.02 | |
| Glutamate receptor 4 | Homo sapiens (human) | 1.02 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bai, R; Jiang, X; Wu, K; Zhang, P; Zhang, Y | 1 |
1 review(s) available for rhc 3164 and 6-cyano-7-nitroquinoxaline-2,3-dione
| Article | Year |
|---|---|
Functionalized quinoxalinones as privileged structures with broad-ranging pharmacological activities.
Topics: Animals; Anti-Allergic Agents; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antineoplastic Agents; Antioxidants; Antiviral Agents; Drug Development; Heterocyclic Compounds; Humans; Hypoglycemic Agents; Mice; Neuroprotective Agents; Photochemotherapy; Quinoxalines; Structure-Activity Relationship; Tubulin Modulators | 2022 |